dose reduction of these medications may be needed) [1] Acute kidney injury risk, particularly with severe gastrointestinal adverse reactions causing dehydration Diabetic retinopathy complications , particularly in patients with a history of retinopathy who experience rapid improvement in blood glucose [1] Acute gallbladder disease including cholelithiasis and cholecystitis The FDA label includes a boxed warning about thyroid C-cell tumors observed in rodent studies, though the relevance to humans remains uncertain
Frequently Asked Questions Are GLP-1 medications safe
Obes Rev 15(7):578586
FDA approval also defines exactly who should use the medication
In a study aimed to establish tirzepatde influence on lipid profile [27], at 26 weeks the three dosages of the drug decreased the levels of apoB, apoC-III levels, large triglyceride-rich lipoprotein particles, and small low-density lipoprotein particles compared with both placebo and dulaglutide
Meanwhile, North America has dominated the GLP-1 agonists weight-loss drug market, accounting for nearly 76% of overall revenue